Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
Evidence continues to build for long-lasting immunity to Covid-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.
Neoleukin was benched by the FDA with a clinical hold for the biopharma company’s lead cancer immunotherapy candidate.
Privately held San Francisco-based programmable cell therapy company ArsenalBio entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
Shares of Mesoblast Limited were down more than 30% in trading following the company’s disappointing announcement regarding a stem-cell therapy trial in ventilator-dependent patients with Covid-19 patients who have moderate-to-severe acute respiratory distress syndrome.
San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.
Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.
The U.S. Food and Drug Administration approved a shorter two-hour infusion time for Roche Group member Genentech’s Ocrevus (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions.